阿托伐他汀作为戊酸倍他米松的辅助药物可降低银屑病的疾病严重程度和心血管风险。
Atorvastatin as an adjuvant with betamethasone valerate reduces disease severity and cardiovascular risks in Psoriasis.
作者信息
Asad Farah, Khan Moosa, Rizvi Fatima
机构信息
Dr. Farah Asad, MBBS, MPhil, Associate Professor, Department of Pharmacology, Jinnah Medical and Dental College, Shaheed-Millat Road, Bhaderabad, Karachi, Pakistan.
Dr. Moosa Khan, MBBS, MPhil, PhD. Head and Professor, Department of Pharmacology, Shaheed Zulfiqar Ali Bhuttoo Medical University, Islamabad, Pakistan.Department of Pharmacology, Jinnah Medical and Dental College, Shaheed-Millat Road, Bhaderabad, Karachi, Pakistan.
出版信息
Pak J Med Sci. 2017 Nov-Dec;33(6):1507-1511. doi: 10.12669/pjms.336.14068.
OBJECTIVES
To evaluate the effect of Atorvastatin as an adjuvant with betamethasone valerate on disease severity and cardiovascular risks in chronic plaque type psoriatic patients.
METHODS
It is an interventional study conducted in Pharmacology Department of BMSI, JPMC with the collaboration of Dermatology Department of JPMC, Karachi. The duration of study was from June 2013 to June 2016. Seventy five psoriatic patients were prescribed Tablet Atorvastatin 40-20 mg/day (40mg for first three months twice daily followed by 20mg once daily for the next three month) plus topical Betamethasone Valerate 0.1% once daily for 6 months (three week apply than one week interval). The efficacy and safety profile of drugs was measured by PASI, DLQI, hsCRP, LFTS and Lipid profile.
RESULTS
The percentage change of PASI is 86.749±0.547, DLQI is 82.697±.2.61 and hsCRP is 40.371±8.505, which showed highly significant improvement in patient at the end of last follow up. LFTs and CPK for safety profile of therapy showed non-significant results.
CONCLUSION
Atorvastatin used as an adjuvant therapy with currently existing standard therapy (topical betamethasone) in patients having mild to moderate plaque type psoriasis reduces disease severity and cardiovascular risks.
目的
评估阿托伐他汀作为戊酸倍他米松的辅助药物，对慢性斑块型银屑病患者疾病严重程度和心血管风险的影响。
方法
这是一项在卡拉奇JPMC的BMSI药理系开展，并与JPMC皮肤科合作进行的干预性研究。研究时间为2013年6月至2016年6月。75例银屑病患者被处方服用阿托伐他汀片，剂量为40 - 20毫克/天（前三个月每天两次，每次40毫克，接下来三个月每天一次，每次20毫克），外加每天一次外用0.1%戊酸倍他米松，共6个月（每三周用药一次，然后间隔一周）。通过银屑病面积和严重程度指数（PASI）、皮肤病生活质量指数（DLQI）、高敏C反应蛋白（hsCRP）以及肝功能检查（LFTS）和血脂谱来衡量药物的疗效和安全性。
结果
PASI的百分比变化为86.749±0.547，DLQI为82.697±2.61，hsCRP为40.371±8.505，这表明在最后一次随访结束时患者有高度显著的改善。用于评估治疗安全性的肝功能检查和肌酸磷酸激酶（CPK）结果无显著差异。
结论
在轻度至中度斑块型银屑病患者中，阿托伐他汀作为现有标准治疗（外用倍他米松）的辅助治疗，可降低疾病严重程度和心血管风险。
Zotero 插件